Clinical outcomes of advanced non-small-cell lung cancer patients with <i>EGFR</i> mutation, <i>ALK</i> rearrangement and <i>EGFR</i>/<i>ALK</i> co-alterations
Na-Na Lou(Southern Medical University), Jin‐Ji Yang(Guangdong General Hospital)
Cited by 39
Related Papers
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
|Journal of Thoracic Disease|2023|9